JEFFREY CHONG: Open Payments
NPI 1376644542 · VAN NUYS, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$570 in 23 payments from 11 companies in 2025. Trend: 2023 $502 · 2024 $639 · 2025 $570
Food & beverage: $570
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC | 5 | $142 |
| Phathom Pharmaceuticals, Inc. | 3 | $88 |
| ABBVIE INC. | 4 | $69 |
| Merck Sharp & Dohme LLC | 2 | $53 |
| SANOFI-AVENTIS U.S. LLC | 2 | $52 |
| AstraZeneca Pharmaceuticals LP | 2 | $49 |
| Otsuka America Pharmaceutical, Inc. | 1 | $29 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $24 |
| GlaxoSmithKline, LLC. | 1 | $24 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $23 |
Products named: VOQUEZNA, VRAYLAR, MOUNJARO, GARDASIL 9, TZIELD, JARDIANCE, REXULTI, ZEPBOUND.
Industry payments across CA — which companies pay providers there.
